<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In rat experiments during <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> (30-min carotid <z:mp ids='MP_0006134'>artery occlusion</z:mp>), ethomersol administered intraperitoneally in a dose of 50 mg/kg before occlusion or at the end of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> eliminated postischemic hypoperfusion </plain></SENT>
<SENT sid="1" pm="."><plain>The effect of the drug was due to its spasmolytic and antiaggregatory activities </plain></SENT>
<SENT sid="2" pm="."><plain>An analysis of the vasodilating action of ethomersol revealed its capacity to block potential-dependent calcium channels and partially intracellular calcium mobilization when the adrenergic and serotoninergic receptors were activated </plain></SENT>
<SENT sid="3" pm="."><plain>The antiaggregatory activity of the drug appeared as inhibited platelet aggregation, which was induced by <z:chebi fb="13" ids="16761">ADP</z:chebi>, <z:chebi fb="19" ids="28790">serotonin</z:chebi>, <z:chebi fb="0" ids="15843">arachidonic acid</z:chebi>, thrombin, and as enhanced antiaggregatory activity of the vascular wall </plain></SENT>
</text></document>